Company Background
HelixNova Labs is the internal AI research group of Novagen Therapeutics, a mid-cap biopharma company focused on immunology and oncology. Novagen has $2.4B in annual revenue, primarily from two marketed immunology drugs, and spends ~$520M/year on R&D. Over the last 24 months, HelixNova has built a machine-learning platform that ingests multi-omics data (RNA-seq, proteomics, clinical labs) and longitudinal EHR-derived phenotypes to identify predictive biomarkers for patient stratification and early efficacy signals.
The platform—internally branded “StrataMap”—was originally justified as a productivity investment for Novagen’s own pipeline. It now supports 6 internal programs and has contributed to two “wins” that leadership is excited about: (1) a Phase 2 oncology trial where biomarker-guided enrollment improved response rate from 18% to 28% in a retrospective analysis, and (2) an immunology program where a stratification hypothesis helped avoid a costly Phase 2b design.
Novagen’s CEO is considering commercializing StrataMap as an external product to diversify revenue and improve investor narrative. The idea is to sell StrataMap as a biomarker discovery + trial enrichment analytics platform to other pharma/biotech companies and possibly to large academic medical centers running investigator-initiated trials.
Strategic Situation (Why Now)
Three forces are pushing this decision:
- Patent cliff risk: Novagen’s top immunology drug faces biosimilar pressure in ~4 years. The CFO wants new revenue streams that are less correlated with single-asset risk.
- Competitive pressure: Several competitors are partnering with AI-biomarker vendors and announcing “precision enrollment” strategies. Novagen worries it will look behind if it doesn’t monetize or at least validate StrataMap externally.
- Regulatory and data landscape shift: In the US and EU, regulators are increasingly open to biomarker-driven trial designs, but data privacy and cross-border transfer requirements are tightening. Commercializing StrataMap could require new compliance investments.
The board has asked for a feasibility assessment of the research ideas behind StrataMap’s next 18-month roadmap and a recommendation on whether to commercialize, who to target first, and what proof points are needed.
Product Concept
StrataMap would be offered as a combination of:
- Software: A secure analytics workspace (cloud or customer VPC) with pre-built pipelines for omics QC, feature engineering, and model development.
- Services: Scientific support for study design, biomarker hypothesis generation, and regulatory documentation.
- Data partnerships (optional): Access to curated reference cohorts through partnerships (where legally permissible).
Two commercialization options are being debated:
- Option A — Enterprise Pharma Platform: Target top 50 global pharma companies with multi-year platform deals.
- Option B — Mid-market Biotech + CRO Channel: Target 200–400 clinical-stage biotechs and partner with 5–10 CROs to embed StrataMap into trial operations.
Market & Competitive Data (Provided)
1) Addressable customer universe (rough)
| Segment | # Orgs (global) | Typical annual R&D spend | Typical trials/year | Buying style |
|---|
| Top 50 Pharma | 50 | $2B–$12B | 50–300 | Central procurement, long cycles |
| Mid-size Pharma | 150 | $300M–$2B | 10–80 | Mixed central + program-led |
| Clinical-stage Biotech | 350 | $30M–$300M | 2–15 | Program-led, faster decisions |
| Large Academic Medical Centers | 120 | N/A | 20–200 IITs | Grant-driven, fragmented |
2) Willingness-to-pay benchmarks (industry interviews)
- Platform subscription for analytics tools: $250K–$1.5M/year (pharma), $75K–$300K/year (biotech)
- Services / scientific support: $150K–$800K per program
- CRO referral/embedding fees: 10–20% of software/services revenue influenced
3) StrataMap current state (internal)
- Team: 22 FTE (12 ML/DS, 6 bioinformatics, 2 product, 2 platform eng)
- Compute: ~$1.8M/year on cloud + storage
- Data assets: 9 internal trial datasets; 2 external licensed cohorts (limited indications)
- Compliance: HIPAA-ready internally; not yet SOC 2 Type II; limited EU GDPR operational maturity
- Current performance claims (not externally validated):
- Biomarker model AUC range: 0.68–0.82 across 4 internal programs
- Retrospective enrichment lift: +10 pp response rate in one oncology dataset
4) Competitive landscape (simplified)
| Competitor type | Examples | Strengths | Weaknesses |
|---|
| AI biomarker startups | (e.g., multi-omics ML vendors) | Speed, modern tooling, strong marketing | Limited trust, smaller datasets, services-heavy margins |
| CRO analytics arms | Large CROs | Embedded in trial ops, distribution | Less innovative ML, slower product cycles |
| Cloud + life sciences platforms | Hyperscalers | Security/compliance, scalable infra | Generic tools, weaker scientific workflow |
Your Role
You are the Strategy Lead reporting to the CEO and Head of R&D. You have 3 weeks to produce a board-ready recommendation.
Deliverables (What you must do)
- Define feasibility for StrataMap’s research ideas: propose a structured rubric to assess whether the next 18-month roadmap is technically and commercially feasible.
- Size the opportunity (TAM/SAM/SOM) for Option A vs Option B using the provided benchmarks and any reasonable assumptions you state.
- Assess competitive dynamics and differentiation using a structured framework (e.g., SWOT + elements of Five Forces).
- Recommend a go-to-market strategy (choose A, B, or a sequenced approach) with pricing/packaging logic and a clear rationale.
- Specify proof points and milestones: what evidence (scientific, product, compliance, customer) must be achieved in 6, 12, and 18 months to de-risk the plan.
Constraints
- Budget for commercialization (incremental): $12M over 18 months (beyond current team/compute)
- Must not materially slow Novagen’s internal pipeline support (CEO insists internal programs remain priority)
- Regulatory/compliance: must be able to support US customers; EU expansion is optional but would be a plus
- Sales capacity: can hire at most 6 net-new GTM FTE in 18 months
- Board target: demonstrate a credible path to $15M ARR within 3 years (not necessarily within 18 months)
